The Department of Health and Human Services is offering the CARB Biopharmaceutical Accelerator Grant to address the insufficiency of candidate antimicrobial products in countering antibiotic resistance. This grant aims to establish a collaborative Accelerator focusing on antibacterial products, providing non-dilutive funding and in-kind services for research and development activities. Managed by a cooperative agreement recipient, the Accelerator will support early-stage antimicrobial product candidates, guiding them from proof-of-concept to pre-clinical development. By enhancing innovation and investment in new antimicrobial products, this grant contributes to the National Strategy for Combating Antimicrobial Resistant Bacteria.
Opportunity ID: 281602
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 13 |
| Posted Date: | Feb 17, 2016 |
| Last Updated Date: | Feb 24, 2016 |
| Original Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) For profit organizations other than small businesses Small businesses Private institutions of higher education Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible.
Application Screening Criteria 1. Applications must be submitted electronically via http://www.grants.gov by April 15, 2016 at 11:59PM 2. Applicants are required to send a letter of intent to the program office by March 10, 2016 at 11:59PM 3. A pre-application workshop will be held on March 3, 2016 from 3:00PM to 5:00PM EST in the Hubert H. 4. A Technical Assistance Conference Call will be held for only parties that have submitted Letters of |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Feb 24, 2016 | ||
| Feb 24, 2016 | ||
| Feb 24, 2016 | ||
| Feb 24, 2016 | ||
| Feb 24, 2016 | ||
| Feb 24, 2016 | ||
| Feb 22, 2016 | ||
| Feb 18, 2016 | ||
| Feb 18, 2016 | ||
| Feb 18, 2016 | ||
| Feb 18, 2016 | ||
| Feb 17, 2016 | ||
| Feb 17, 2016 |
DISPLAYING: Synopsis 13
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 13 |
| Posted Date: | Feb 17, 2016 |
| Last Updated Date: | Feb 24, 2016 |
| Original Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) For profit organizations other than small businesses Small businesses Private institutions of higher education Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible.
Application Screening Criteria 1. Applications must be submitted electronically via http://www.grants.gov by April 15, 2016 at 11:59PM 2. Applicants are required to send a letter of intent to the program office by March 10, 2016 at 11:59PM 3. A pre-application workshop will be held on March 3, 2016 from 3:00PM to 5:00PM EST in the Hubert H. 4. A Technical Assistance Conference Call will be held for only parties that have submitted Letters of |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 12
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 12 |
| Posted Date: | Feb 24, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible.
Application Screening Criteria 1. Applications must be submitted electronically via http://www.grants.gov by April 15, 2016 at 11:59PM 2. Applicants are required to send a letter of intent to the program office by March 10, 2016 at 11:59PM 3. A pre-application workshop will be held on March 3, 2016 from 3:00PM to€“ 5:00PM EST in the Hubert H. 4. A Technical Assistance Conference Call will be held for only parties that have submitted Letters of |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 11
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 11 |
| Posted Date: | Feb 24, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible.
Application Screening Criteria 1. Applications must be submitted electronically via http://www.grants.gov by April 15, 2016 at 11:59PM 2. Applicants are required to send a letter of intent to the program office by March 10, 2016 at 11:59PM 3. A pre-application workshop will be held on March 3, 2016 from 3:00PM – 5:00PM EST in the Hubert H. 4. A Technical Assistance Conference Call will be held for only parties that have submitted Letters of |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 10
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 10 |
| Posted Date: | Feb 24, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible.
Application Screening Criteria 1. Applications must be submitted electronically via http://www.grants.gov by April 15, 2016 at 11:59PM 2. Applicants are required to send a letter of intent to the program office by March 10, 2016 at 11:59PM 3. A pre-application workshop will be held on March 3, 2016 from 3:00PM to€“ 5:00PM EST in the Hubert H. 4. A Technical Assistance Conference Call will be held for only parties that have submitted €œLetters of |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 9
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 9 |
| Posted Date: | Feb 24, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible.
Application Screening Criteria 1. Applications must be submitted electronically via http://www.grants.gov by April 15, 2016 at 11:59PM 2. Applicants are required to send a letter of intent to the program office by March 10, 2016 at 11:59PM 3. A pre-application workshop will be held on March 3, 2016 from 3:00PM – 5:00PM EST in the Hubert H. 4. A Technical Assistance Conference Call will be held for only parties that have submitted “Letters of |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 8
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 8 |
| Posted Date: | Feb 24, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible. |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 7
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 7 |
| Posted Date: | Feb 22, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible. |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 6
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 6 |
| Posted Date: | Feb 18, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible. |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 5
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 5 |
| Posted Date: | Feb 18, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible. |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 4
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 4 |
| Posted Date: | Feb 18, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible. |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Feb 18, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible. |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Feb 17, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible. |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | EP-IDS-16-001 |
| Funding Opportunity Title: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 93.360 — Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 17, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 15, 2016 Applications must be submitted electronically through www.grants.gov by the application deadline of April 15, 2016 at 11:59PM EDT. ASPR will not accept any applications that are not submitted electronically via www.grants.gov. |
| Archive Date: | May 15, 2016 |
| Estimated Total Program Funding: | $250,000,000 |
| Award Ceiling: | $30,000,000 |
| Award Floor: | $30,000,000 |
Eligibility
| Eligible Applicants: | Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Research institutions and Non-domestic (non-U.S.) entities are eligible. |
Additional Information
| Agency Name: | Assistant Secretary for Preparedness and Response |
| Description: | The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates. |
| Link to Additional Information: | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Grants.gov Contact Center
Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email:support@grants.gov |
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | Grants.gov Contact Center Phone Number: 1-800-518-4726 Hours of operation are 24 hours a day, 7 days a week. The contact center is closed on federal holidays. Email: support@grants.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.360 | EP-IDS-16-001-055678 | Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator | PKG00221033 | Feb 16, 2016 | Apr 15, 2016 | View |
Package 1
Mandatory forms
281602 SF424_2_1-2.1.pdf
281602 Project-1.1.pdf
281602 Budget-1.1.pdf
281602 SF424A-1.0.pdf
281602 SF424B-1.1.pdf
Optional forms
281602 Other-1.1.pdf
281602 PerformanceSite_1_4-1.4.pdf
281602 Project_Abstract-1.1.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
